Incidence rates of amputations in patients with diabetes in Denmark have been decreasing continuously for the last four decades, but further reduction is still needed

IF 3.2 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ole Lander Svendsen
{"title":"Incidence rates of amputations in patients with diabetes in Denmark have been decreasing continuously for the last four decades, but further reduction is still needed","authors":"Ole Lander Svendsen","doi":"10.1111/dme.15413","DOIUrl":null,"url":null,"abstract":"<p>Worldwide, a patient with diabetes is amputated every 30 s, and patients with diabetes fear amputation, with the loss of limbs and mobility, more than any other late diabetic complication, including death.<span><sup>1</sup></span></p><p>The incidence of lower extremity amputations (LEA) in patients with diabetes has been much higher than in patients without diabetes, with a 12-fold higher risk in the UK in the early 1990s.<span><sup>2</sup></span> The Saint Vincent Declaration from Europe, 1989, aimed for a reduction by half of LEA within 5 years in patients with diabetes.</p><p>In the United States, there has been a resurgence of LEA in patients with diabetes,<span><sup>3</sup></span> which has caused the American Heart Association to set a goal of reducing the incidence rate of LEA by 20% by 2030.<span><sup>4</sup></span> Furthermore, a new declaration for feet's sake: halving the global diabetic foot disease burden, from 2% to 1% with next-generation care, has recently been suggested by members of the International Working Group on the Diabetic Foot.<span><sup>5</sup></span></p><p>In 2022 in Denmark, an ‘Amputation Scandal’, where patients had been amputated unnecessarily, was described by Danish Press. The reason was a high frequency of LEA in the Central Region of Jutland compared with other Regions of Denmark, caused by cuts in budgets for vascular surgery. A later analysis also showed regional differences, where the annual rate of LEA was halved in the Capital Region, but was increased by 10% in Region Zealand, from 2016 to 2021,<span><sup>6</sup></span> probably due to differences in socioeconomic and health status, as well as access to health services and general practitioners. However, the impact of diabetes was not reported.</p><p>Several studies have examined the incidence rates of LEA in patients with diabetes in Denmark (Table 1).<span><sup>7</sup></span> As shown in Table 1, significant decreases in the incidence rates of LEA in patients with diabetes have occurred in all the studies over the past 40 years. Several of the studies in the table suggest that the reasons for the significant decrease in incidence rates of LEA in patients with diabetes are increased vascular surgical treatment, establishment of multidisciplinary teams to handle foot ulcers in patients with diabetes, better treatment of metabolic and lifestyle factors, improved organization of diabetes foot clinics, better and more aggressive early prevention and treatment of foot ulcers, and improved patient education.</p><p>In the latest national study of non-traumatic LEA in Denmark from 1997 to 2017, 60% had diabetes.<span><sup>8</sup></span> The total number of LEA had increased, both in people with and without diabetes, probably because the number of elderly and people with diabetes in Denmark had increased. However, the incidence rate of major LEA decreased by 2–9% per year and minor LEA by 6–7% per year in patients with diabetes. In people without diabetes, the incidence rate of both major and of minor LEA decreased by about 1% per year. In 2017, the incidence rate (per 100,000 patient-years) of transfemoral amputations, transtibial amputations and minor LEA was approximately 70, 40 and 120 in patients with type 2 diabetes; 10, 20 and 120 in patients with type 1 diabetes, and 20, 15 and 30 for individuals without diabetes. Thus, the risk of LEA for an individual patient with diabetes has decreased but was still two to four times higher than in individuals without diabetes.</p><p>The time interval from vascular surgical intervention to LEA had increased from 1997 to 2017, from under 6 months to 2 years for minor LEA, 3 years for transtibial amputations and 4 years for transfemoral amputations, and was similar for patients with and without diabetes.<span><sup>8</sup></span> Thus, Danish patients with diabetes who undergo vascular surgery have the same effect of the procedure as patients without diabetes, with a ‘lifetime’ of the limb of up to 4 years without amputation.</p><p>One-year mortality rates in patients with diabetes were approximately 50%, 30% and 20% after transfemoral amputation, transtibial amputation and minor LEA, respectively, while the 5-year mortality rates were approximately 75%, 67% and 45%.<span><sup>8</sup></span> Advanced age and comorbidity, but not diabetes, were associated with increased mortality.<span><sup>9, 10</sup></span></p><p>Evidence-based guidelines from the International Working Group on Diabetic Foot (www. iwgdfguidelines.org) have recently been updated and are recommended to further reduce LEAs in patients with diabetes. In Denmark, the National Treatment Guideline for the treatment of diabetic foot disease from the Danish Endocrinology Society is recommended. However, monitoring the quality of care is important. The Danish Adult Diabetes Database report for 2021–2022, shows that only 71% of patients with diabetes in hospital-based diabetes outpatient clinics had undergone the recommended annual preventive foot examination, whereas in general practice, 30% of patients with diabetes had undergone the preventive annual foot examination. The low percentage receiving the annual preventive foot examination is far from the goal.</p><p>This underscores the need for continuously ongoing monitoring of quality of care and treatment of diabetic foot diseases.</p><p>The author has no potential conflict of interest relevant to this letter.</p>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":"41 11","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15413","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.15413","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Worldwide, a patient with diabetes is amputated every 30 s, and patients with diabetes fear amputation, with the loss of limbs and mobility, more than any other late diabetic complication, including death.1

The incidence of lower extremity amputations (LEA) in patients with diabetes has been much higher than in patients without diabetes, with a 12-fold higher risk in the UK in the early 1990s.2 The Saint Vincent Declaration from Europe, 1989, aimed for a reduction by half of LEA within 5 years in patients with diabetes.

In the United States, there has been a resurgence of LEA in patients with diabetes,3 which has caused the American Heart Association to set a goal of reducing the incidence rate of LEA by 20% by 2030.4 Furthermore, a new declaration for feet's sake: halving the global diabetic foot disease burden, from 2% to 1% with next-generation care, has recently been suggested by members of the International Working Group on the Diabetic Foot.5

In 2022 in Denmark, an ‘Amputation Scandal’, where patients had been amputated unnecessarily, was described by Danish Press. The reason was a high frequency of LEA in the Central Region of Jutland compared with other Regions of Denmark, caused by cuts in budgets for vascular surgery. A later analysis also showed regional differences, where the annual rate of LEA was halved in the Capital Region, but was increased by 10% in Region Zealand, from 2016 to 2021,6 probably due to differences in socioeconomic and health status, as well as access to health services and general practitioners. However, the impact of diabetes was not reported.

Several studies have examined the incidence rates of LEA in patients with diabetes in Denmark (Table 1).7 As shown in Table 1, significant decreases in the incidence rates of LEA in patients with diabetes have occurred in all the studies over the past 40 years. Several of the studies in the table suggest that the reasons for the significant decrease in incidence rates of LEA in patients with diabetes are increased vascular surgical treatment, establishment of multidisciplinary teams to handle foot ulcers in patients with diabetes, better treatment of metabolic and lifestyle factors, improved organization of diabetes foot clinics, better and more aggressive early prevention and treatment of foot ulcers, and improved patient education.

In the latest national study of non-traumatic LEA in Denmark from 1997 to 2017, 60% had diabetes.8 The total number of LEA had increased, both in people with and without diabetes, probably because the number of elderly and people with diabetes in Denmark had increased. However, the incidence rate of major LEA decreased by 2–9% per year and minor LEA by 6–7% per year in patients with diabetes. In people without diabetes, the incidence rate of both major and of minor LEA decreased by about 1% per year. In 2017, the incidence rate (per 100,000 patient-years) of transfemoral amputations, transtibial amputations and minor LEA was approximately 70, 40 and 120 in patients with type 2 diabetes; 10, 20 and 120 in patients with type 1 diabetes, and 20, 15 and 30 for individuals without diabetes. Thus, the risk of LEA for an individual patient with diabetes has decreased but was still two to four times higher than in individuals without diabetes.

The time interval from vascular surgical intervention to LEA had increased from 1997 to 2017, from under 6 months to 2 years for minor LEA, 3 years for transtibial amputations and 4 years for transfemoral amputations, and was similar for patients with and without diabetes.8 Thus, Danish patients with diabetes who undergo vascular surgery have the same effect of the procedure as patients without diabetes, with a ‘lifetime’ of the limb of up to 4 years without amputation.

One-year mortality rates in patients with diabetes were approximately 50%, 30% and 20% after transfemoral amputation, transtibial amputation and minor LEA, respectively, while the 5-year mortality rates were approximately 75%, 67% and 45%.8 Advanced age and comorbidity, but not diabetes, were associated with increased mortality.9, 10

Evidence-based guidelines from the International Working Group on Diabetic Foot (www. iwgdfguidelines.org) have recently been updated and are recommended to further reduce LEAs in patients with diabetes. In Denmark, the National Treatment Guideline for the treatment of diabetic foot disease from the Danish Endocrinology Society is recommended. However, monitoring the quality of care is important. The Danish Adult Diabetes Database report for 2021–2022, shows that only 71% of patients with diabetes in hospital-based diabetes outpatient clinics had undergone the recommended annual preventive foot examination, whereas in general practice, 30% of patients with diabetes had undergone the preventive annual foot examination. The low percentage receiving the annual preventive foot examination is far from the goal.

This underscores the need for continuously ongoing monitoring of quality of care and treatment of diabetic foot diseases.

The author has no potential conflict of interest relevant to this letter.

过去四十年来,丹麦糖尿病患者的截肢率持续下降,但仍需进一步降低。
这强调了对糖尿病足疾病的护理和治疗质量进行持续不断监测的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetic Medicine
Diabetic Medicine 医学-内分泌学与代谢
CiteScore
7.20
自引率
5.70%
发文量
229
审稿时长
3-6 weeks
期刊介绍: Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信